Sandie Yu

Sandie Yu has extensive experience in market access and health economics in the pharmaceutical and biotechnology industry. Sandie has held leadership positions at various companies, including Day One Biopharmaceuticals, where they currently serve as the VP of Market Access and HEOR Strategy. Prior to that, they worked as a Market Access and Global HEOR Advisor, providing strategic consulting services to start-up biotech companies.

Sandie also served as the Executive Director and Head of Market Access & Global Health Economics at LOXO Oncology, Inc., where they successfully launched the first molecularly defined oncology product, VITRAKVI. Sandie has experience in global health outcome data generation, pricing and reimbursement strategies, and interactions with payers.

Before joining LOXO Oncology, Sandie worked at Medivation as the Senior Director and Head of Market Access, Patient Advocacy, and Government Policy. Sandie played a key role in the launch of Xtandi, a prostate cancer product, and managed the market access work streams for the company's Phase 1-4 assets.

Sandie's earlier experience includes roles at Genentech and Roche Laboratories, where they held positions such as Marketing Director and Product Director, leading cross-functional teams and developing marketing strategies for various products. Sandie has a proven track record of successfully launching new indications and repositioning products in the market.

Overall, Sandie Yu has a diverse background in market access, health economics, and pharmaceutical marketing, with a strong focus on strategic planning, pricing and reimbursement, and commercialization of innovative therapies.

Sandie Yu pursued their undergraduate degree in Science/Biology at the University of California, Davis. The exact time period of their undergraduate studies is not specified. Subsequently, they attended the Cornell Johnson Graduate School of Management from 2000 to 2002, where they earned their Master of Business Administration (MBA) degree.